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510 L.-S. Syue et al.Results: The study population consisted of 77 cirrhotic patients with Aeromonas bacteremia
and 48 patients with Vibrio bacteremia. Both pathogens clustered during the summer season;
Vibrio bacteremia was more correlated with higher temperatures (Vibrio: r2 Z 0.95,
p < 0.0001; Aeromonas: r2 Z 0.74, p Z 0.006) and was associated with ingestion of under-
cooked seafood (p Z 0.03) or cutaneous exposure (p < 0.001). Vibrio bacteremia mainly
occurred in mildly or moderately decompensated cirrhosis (ChildePugh class A and B: 45.8%
vs. 20.8%, p Z 0.003), and caused more soft-tissue infections (31.3% vs. 5.2%; p < 0.001)
and renal dysfunction (1.6  1.2 mg/dL vs. 1.3  0.8 mg/dL, p Z 0.006). Sepsis-related mor-
tality was similar in the cases of Vibrio and Aeromonas bacteremia (14.6% vs. 14.3%, pZ 0.96),
but those with Vibrio bacteremia underwent a fulminant course, as evidenced by a shorter
time from bacteremia onset to death (3.1 days vs. 8.2 days, p Z 0.04).
Conclusion: In cirrhotic patients, bacteremia caused by Aeromonas and Vibrio species clus-
tered in summer months and caused similar mortality, but Vibrio bacteremia led to a more se-
vere and fulminant sepsis.
Copyright ª 2014, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Bacterial infections remained common and accounted for
significant morbidity and mortality in cirrhotic patients.
The cumulative mortality rate after infections in cirrhotic
patients could be up to 43.5%, four-fold higher than those
without infections.1 Approximately 76% of bacteremia in
cirrhotic patients were caused by Gram-negative bacteria,
and Escherichia coli and Klebsiella spp. were the most
common microorganisms.2 Vibrio, Aeromonas, and
Campylobacter spp. occasionally caused bacteremia in
cirrhotic patients, but these individuals are at great risks
for invasive infections caused by these less commonly
encountered pathogens.3 Previous studies have described
the clinical features, infection foci, and short-term
outcome of Aeromonas or Vibrio infections, such as pri-
mary bacteremia, spontaneous bacterial peritonitis, or soft
tissue infection, especially in patients with hepatic prob-
lems. Their occurrence may be related to food or water
exposure.4e6 Taiwan, especially its southern region, could
be regarded as one of the endemic areas of Aeromonas and
Vibrio infections because of their ubiquitous presence in
the environment and the high incidence of chronic hepa-
titis.7 However, a poor outcome had been prescribed in the
cases of Aeromonas or Vibrio infections,8 and underlying
hepatic cirrhosis is often referred to as a prognostic host
factor.8,9 Empirical antimicrobial therapy that covers both
pathogens among the susceptible population is an impor-
tant clinical issue in Taiwan.
Recently, among clinical Aeromonas isolates b-lacta-
mases conferring cephalosporin resistance, which were
absent in clinical Vibrio isolates, had been discussed,10 and
such a finding highlighted the importance of the identifi-
cation of the Aeromonas genus. However, infectious dis-
eases caused by Aeromonas or Vibrio species could not be
clinically distinguished. So far, there is no study detailing
their similarities and dissimilarities among cirrhotic pa-
tients. Therefore, our study was intended to describe and
compare the clinical features and outcome of Aeromonas
and Vibrio bacteremia in cirrhotic patients who sought
treatment at a medical center in southern Taiwan.Materials and methods
The cases of Aeromonas and Vibrio bacteremia between
January 2003 and September 2013 were identified from the
database of the Microbiology Laboratory of National Cheng
Kung University Hospital, Tainan, Taiwan. Clinical and lab-
oratory information, including demographic characteris-
tics, underlying disease, clinical presentations and course,
laboratory data, antimicrobial agents administered, and
clinical outcomes, were collected. The clinical diagnosis of
liver cirrhosis was made by sonographic findings in
conjunction with the presence of cirrhotic complications,
such as ascites, esophageal varices, hepatic encephalopa-
thy, or coagulopathy. Only monomicrobial bacteremia was
included. The monthly mean outdoor temperatures (C) in
the Tainan area between 2003 and 2013 were obtained from
the Central Weather Bureau, Taiwan, and would be used to
correlate with the seasonal distribution of all episodes of
monomicrobial Aeromonas and Vibrio bacteremia. Only the
first episode of Aeromonas or Vibrio bacteremia was taken
into account in other analyses in this study.
The blood culture system used was BACTEC 9240 (Beckon
Dickinson, Sparks, MD, USA). Identification of the Aeromonas
genus was based on a positive oxidase test, fermentation of
D-glucose, the absence of growth in 6.5% sodium chloride,
and resistance to the vibriostatic agent, 0/129 (150 mg), as
described previously.11 Because recent advances in nomen-
clature in the genus Aeromonas are based on genetic iden-
tification, which led to a reclassification of the Aeromonas
species,12 species identification is beyond the scope of this
study, and only the details of Aeromonas bacteremia are
discussed. Vibrio isolates identified were oxidase positive,
susceptible to 0/129, tolerable to salt solution, and can
ferment glucose. Species identification relied on typical
biochemistry characteristics as described previously.5 Both
genera were confirmed using the commercial identification
system, API 20E system (BioMe´rieux, Marcy-l’E´toile, France).
Serotyping of Vibrio cholerae was studied by the O1 anti-
serum. In vitro antimicrobial susceptibilities of all isolates
were determined with the disk diffusion method described
by the Clinical and Laboratory Standards Institute.13
Figure 1. Seasonal distribution of Aeromonas and Vibrio
bacteremia in cirrhotic patients in southern Taiwan. There is a
more significant correlation of Vibrio bacteremia episodes
(r2 Z 0.95, p < 0.0001) with average ambient temperature
than those of Aeromonas bacteremia (r2 Z 0.74, p Z 0.006,
Spearman’s correlation). P Z 0.04.
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episodes detected at least 72 hours after admission. The
severity of liver cirrhosis was assessed by the Pugh scoring
system based on serum albumin, total serum bilirubin,
prolongation of prothrombin time, amount of ascites, and
degree of hepatic encephalopathy.14 Patients who had
antecedent trauma, fish bone injury, or recent contact with
freshwater or seawater, were reported as cutaneous
exposure. Recent consumption of uncooked seafood was
regarded as ingestion exposure. Bacteremia without
concomitant attributable infectious focus was considered
primary bacteremia, and other infectious foci were deter-
mined on the basis of clinical findings or bacterial culture
results. Hypotension was defined as a systolic blood pres-
sure <90 mmHg or the need for an inotropic agent support
within 24 hours prior to or 48 hours after bacteremia onset.
The severity of illness was graded using the Pitt bacteremia
score, which was based on the evaluation of body tem-
perature, mental status, blood pressure, need for me-
chanical ventilation, and presence of cardiac arrest.15
When the septic process was deemed to be the cause of
death, the fatality was regarded as being directly related to
the bacteremia. Deaths resulting from any events other
than septicemia, such as gastrointestinal bleeding or un-
derlying problem, were defined as not directly related to
bacteremia. Initial antimicrobial therapy was the drug
prescribed continuously for at least 48 hours after the
symptom onset. If it was demonstrated to be in vitro active
against the causative pathogen, it was defined as being
appropriate.
Statistical analyses were performed using SPSS, version
17.0 (SPSS Inc., Chicago, IL, USA). Pearson’s Chi-square test
or two-tailed Fisher’s exact test was used to examine
nominal data and unpaired Student t test was used for
continuous data. ManneWhitney U test was used for
outcome analysis, and KaplaneMeier survival curves were
performed for the survival duration of Aeromonas and
Vibrio species. The correlation of monthly episodes of
bacteremia and the average outdoor temperature in Tainan
City were examined using the Spearman correlation anal-
ysis. A p value of 0.05 was regarded as statistically
significant.Results
Between January 2003 and September 2013, a total 240
Aeromonas isolates obtained from 227 patients and 92
Vibrio isolates from 91 patients were found. Among these
patients, 77 (33.9%) patients with 86 episodes of Aeromonas
bacteremia and 48 (52.7%) patients with 49 episodes of
Vibrio bacteremia had hepatic cirrhosis. Regarding Vibrio
bacteremia, 27 episodes were caused by Vibrio vulnificus,
20 by non-O1, non-O139 V. cholera, and two by Vibrio spp.
Compared with Aeromonas bacteremia, Vibrio bacteremia
was more correlated with warmer temperatures (Aero-
monas: r2Z 0.74, pZ 0.006; Vibrio: r2Z 0.95, p < 0.0001)
(Fig. 1).
The mean age of patients with Aeromonas bacteremia
was 57.0 years (range, 29e93 years) and that of patients
with Vibrio bacteremia was 55.4 years (range, 35e84 years)
(Table 1). Males predominated in both groups. Diabetesmellitus and hepatocellular carcinoma, in addition to
cirrhosis, were common comorbidities in both groups.
Nosocomial acquisition was more common in Aeromonas
bacteremia than in Vibrio bacteremia (23.4% vs. 8.3%,
p Z 0.03). The interval between the admission and acqui-
sition of Aeromonas bacteremia tended to be longer than
that of Vibrio bacteremia (14.8 days vs. 7.0 days,
p Z 0.39), although the difference was not statically
significant.
Only two (2.6%) patients with Aeromonas bacteremia
were associated with an exposure history, but for Vibrio
bacteremia, six (12.5%) patients with seafood exposure
(pZ 0.03) and 14 (29.2%) patients with cutaneous exposure
(p < 0.001) were noted. Vibrio bacteremia occurred in
cases of mild-to-moderate decompensated cirrhosis
(ChildePugh class A and B: 45.8% vs. 20.8%, p Z 0.003),
whereas Aeromonas bacteremia often occurred in those
with severely decompensated cirrhosis.
As for clinical manifestations, the initial presentation of
fever was common at arrival. Of note, patients with Vibrio
bacteremia more often experienced dyspnea (33.3% vs.
15.6%, pZ 0.02) and tended to have more severe sepsis, as
indicated by more patients with a Pittsburgh bacteremia
score 4 (33.3% vs. 19.5%, p Z 0.08; Table 1). In terms of
leukocytosis, leukopenia, or thrombocytopenia, there were
no differences, but serum creatinine levels at initial pre-
sentation were higher in the cases of Vibrio bacteremia
(1.6  1.2 mg/dL vs. 1.3  0.8 mg/dL; p Z 0.006).
As for the potential source or infectious focus of
bloodstream infections, primary bacteremia was most
common in both study groups (Aeromonas: 43/77, 55.8%;
Vibrio: 22/48, 45.8%; p Z 0.28), followed by spontaneous
bacterial peritonitis (Aeromonas: 21/77, 27.3%; Vibrio: 7/
48, 14.6%; p Z 0.10). Of note, soft-tissue infections were
more common in Vibrio bacteremia (15/48, 31.3% vs. 4/77,
5.2%; p < 0.001) (Fig. 2). Four cases of Aeromonas
bacteremia and soft-tissue infections had necrotizing fas-
ciitis. Of 15 cases of Vibrio bacteremia and soft-tissue in-
fections, 86.7% (13) had necrotizing fasciitis requiring
emergent fasciotomy. The other infectious foci included
intra-abdominal infections (3 cases of Aeromonas
Table 1 Clinical characteristics of cirrhotic patients with Aeromonas or Vibrio bacteremia
Characteristic Case no. (%) or mean  standard deviation p value
Aeromonas, n Z 77 Vibrio, n Z 48
Age, year 57.0  13.9 55.4  12.6 0.28
Male 53 (68.8) 34 (70.8) 0.81
Healthcare-associated bacteremia 18 (23.4) 4 (8.3) 0.03
Days after admission, mean (range)a 14.8 (3e46) 7 (3e15) 0.39
Etiology of liver cirrhosis
Hepatitis B virus 45 (58.4) 22 (45.8) 0.17
Hepatitis C virus 22 (28.6) 15 (31.3) 0.75
Alcoholism 18 (23.4) 13 (27.1) 0.64
Mild-to-moderate cirrhosisb 16 (20.8) 22 (45.8) 0.003
Comorbid conditions
Hepatocellular carcinoma 35 (45.5) 17 (35.4) 0.27
Diabetes mellitus 17 (22.1) 16 (33.3) 0.17
Malignancy other than hepatoma 5 (6.5) 4 (8.3) 0.70
Chronic kidney disease 4 (5.2) 1 (2.1) 0.39
Steroid use 0 2 (4.2) 0.07
Exposure history
Ingestion exposure 2 (2.6) 6 (12.5) 0.03
Cutaneous exposure to water or trauma 0 14 (29.2) <0.001
Prior antibiotics within 1 month before onset 18 (23.4) 6 (12.5) 0.13
Clinical presentations
Fever 74 (96.1) 43 (89.6) 0.15
Hypotension 29 (37.7) 25 (52.1) 0.11
Altered mental status 24 (31.2) 10 (20.8) 0.21
Dyspnea 12 (15.6) 16 (33.3) 0.02
Abdominal pain 28 (36.4) 13 (27.1) 0.28
Diarrhea 14 (18.2) 4 (8.3) 0.13
Laboratory data
Leukocytosis (>12,000/mm3) 16 (20.8) 11 (22.9) 0.78
Leukopenia (<4000/mm3) 16 (20.8) 13 (27.1) 0.42
Thrombocytopenia (<100,000/mm3) 63 (81.8) 40 (83.3) 0.83
Serum creatinine (mg/dL) 1.3  0.8 1.6  1.2 0.006
Pittsburgh bacteremia score 4 15 (19.5) 16 (33.3) 0.08
a Two cases transferred from other hospitals without complete information were excluded.
b Child-Pugh class A and B.
Figure 2. Infectious foci of Aeromonas or Vibrio bacteremia
in cirrhotic patients. Vibrio bacteremia more often manifests
as soft-tissue infections than Aeromonas bacteremia (15/48,
31.3% vs. 4/77, 5.2%; p < 0.001).
512 L.-S. Syue et al.infection, 3 cases of Vibrio infection), spontaneous bacte-
rial empyema (3 cases of Aeromonas, 1 case of Vibrio),
biliary tract infection (1 case of Aeromonas), urinary tract
infection (1 case of Aeromonas), and pneumonia (1 case of
Aeromonas). Of the patients with Vibrio bacteremia, four
(30.8%) of 13 with necrotizing fasciitis and 12 (34.3%) of 35
without necrotizing fasciitis had severe illness (Pitt
bacteremia score  4), compared with 15 (19.5%) of 77
with Aeromonas bacteremia (p Z 0.36 and p Z 0.09,
respectively).
Of the cases of Aeromonas and Vibrio bacteremia, there
were no differences in crude (20.8% vs. 29.2%, pZ 0.29) or
sepsis-related mortality rate (14.3% vs. 14.6%, p Z 0.96)
(Table 2). However, the interval between the bacteremia
onset to sepsis-related death was shorter in the cases of
Vibrio bacteremia than that of Aeromonas bacteremia (3.1
days vs. 8.2 days, p Z 0.04) (Fig. 3).
Interestingly, three cirrhotic cases of Aeromonas
bacteremia experienced Vibrio bacteremia at 2e12 months
after the previous Aeromonas episodes. By contrast, four
Table 2 Clinical outcome of Aeromonas or Vibrio bacteremia in cirrhotic patients
Variables Case no. (%) p value
Aeromonas, n Z 77 Vibrio, n Z 48
Appropriate antibiotics initially 61 (79.2) 43 (89.6) 0.13
Hospital stay, days
All cases (mean, range) 16.1 (1-80) 17.4 (1-67) 0.83
Survivors (mean, range) 14.4 (4-80) 19.0 (1-67) 0.56
Intensive care unit admission 9 (11.7) 10 (20.8) 0.17
Mortality
Sepsis-related 11 (14.3) 7 (14.6) 0.96
At 14 days 10 (13.0) 10 (20.8) 0.25
At 1 month 16 (20.8) 13 (27.1) 0.42
In hospital 16 (20.8) 14 (29.2) 0.29
Aeromonas and Vibrio bacteremia in cirrhotic adults 513cirrhotic cases of Vibrio bacteremia experienced Aero-
monas bacteremia at 22e68 months afterward (Table 3).
Discussion
Both Aeromonas and Vibrio spp. are important pathogens
that cause clinical infections, including primary bacter-
emia, spontaneous bacterial peritonitis, soft-tissue in-
fections, and gastroenteritis, especially in regions with a
high prevalence of chronic hepatitis and warm climate,
such as Taiwan. The individual characteristics of clinical
presentations and outcomes of human infections due to
Aeromonas and Vibrio species, which often were linked to
wild water exposure, had been well described.5,6,16 How-
ever, no report ever compared the clinical characteristics
of cirrhotic patients with Aeromonas and Vibrio infections.
To our knowledge, this is the first report to investigate the
differences in clinical manifestations.Figure 3. KaplaneMeier survival curves of cirrhotic patients
with sepsis-related mortality due to Aeromonas or Vibrio
bacteremia. The mean duration after bacteremia onset to
death was significantly shorter in those with Vibrio bacteremia
than in those with Aeromonas bacteremia (3.1 days vs. 8.2
days, p Z 0.04).As compared with Western countries, the incidence of
Aeromonas bacteremia in southern Taiwan was 143-, 50-,
and 115-fold higher than those in California in 1998, En-
gland and Wales in 2004, and France in 2006, respectively,
whereas non-cholerae Vibrio bacteremia was 50-fold higher
than that in Florida, USA.7 Prior to 2000, the predominance
of underlying cirrhosis in the cases of Aeromonas and non-
O1, non-O139 V. cholerae bacteremia has been recog-
nized in Taiwan.5,17 In this study, 33.9% of monomicrobial
Aeromonas bacteremia and 52.7% of Vibrio bacteremia
were found in cirrhotic patients. These epidemiological
figures highlighted the endemicity of Aeromonas and Vibrio
bacteremia in Taiwan.
As compared with other underlying diseases, cirrhosis
posed a significant impact on the mortality of patients with
community-acquired bacteremia.18 Although medical care
of cirrhotic patients had been improved in the past decades
and prophylactic antibiotics had been utilized under
certain conditions, including gastrointestinal bleeding or
while undergoing invasive procedures,19 bacterial in-
fections cause substantial morbidity and mortality among
cirrhotic patients.20 Those with decompensated hepatic
function are in a multifactorial state of local and systemic
immune dysfunction,21 including portosystemic shunting
allowing more endotoxins in the portal circulation to bypass
the liver,22 impaired phagocyte activity and opsonic activ-
ity,23 and bacterial translocation.24 Moreover, as hepatic
decompensation progressed, it is often associated with
bloodstream infections and a worse outcome.25 The exact
mechanism may be, at least partially, related to bacterial
translocation.26
Specific virulence-associated genes and markers of Aer-
omonas and Vibrio species had been studied,27 but the
reasons why invasive infections attributed to both patho-
gens dominated in cirrhotic patients remain unsettled.28
However, previous studies have been addressed wherein
cases of Aeromonas and Vibrio infections were more com-
mon in the ChildePugh class C of decompensation,5,17 and
the average ChildePugh score was higher in cirrhotic pa-
tients with Aeromonas infections than those with infections
due to other bacterial species.29
In this study, seven patients had sequential Aeromonas
and Vibrio bacteremia at different intervals (2e64 months).
Those with initial Vibrio bacteremia tended to have mild-
to-moderate cirrhosis and developed Aeromonas
Table 3 Clinical characteristics of seven cirrhotic patients with sequential Aeromonas and Vibrio vulnificus or non-O1, non-
O139 V. cholerae bacteremia
Case no. Age/sex Comorbidities Pugh classa Date/Pathogen/Clinical diagnosis Outcome of 2nd
episode1st episode 2nd episode Interval
1 44/M Hepatoma,
diabetes
mellitus
C/C 2003.05/Aeromonas/
primary
bacteremia
2003.07/V. cholerae/
primary
bacteremia
2 months Survived
2 69/F Hepatoma C/C 2008.04/Aeromonas/
SBP
2008.07/V. choleraeb/
SBE
3 months Died
3 55/F No C/C 2010.02/Aeromonas/
primary
bacteremia
2011.02/V. vulnificus/
primary
bacteremia
12 months Survived
4 41/M Diabetes
mellitus
A/C 2003.10/V. vulnificus/
primary
bacteremia
2009.06/Aeromonas/
primary
bacteremia
68 months Survived
5 57/F Hepatoma C/C 2004.09/V. vulnificus/
primary
bacteremia
2006.07/Aeromonasb/
primary
bacteremia
22 months Died
6 39/M Squamous
cell
carcinoma
B/C 2007.08/V. cholerae/
SBP
2009.10/Aeromonas/
SBP
26 months Survived
7 68/F Diabetes
mellitus
B/C 2010.08/V. cholerae/
enteritis
2012.08/Aeromonas/
pneumonia
24 months Survived
a Pugh class of 1st episode/2nd episode.
b Hospital-associated infections.
SBP Z spontaneous bacterial peritonitis; SBE Z spontaneous bacterial empyema.
514 L.-S. Syue et al.bacteremia later, while liver function deteriorated. As
compared with those with Aeromonas infections, Vibrio
infections developed in individuals with less severe hepatic
dysfunction, suggestive of a higher virulence of Vibrio iso-
lates. Moreover, we found that patients with Vibrio
bacteremia experienced more hypotension, renal function
deterioration, and a high disease severity than those with
Aeromonas bacteremia. Furthermore, Vibrio sepsis runs a
fulminant clinical course, that is, a shorter interval be-
tween disease onset to death. The above facts indicate that
Vibrio spp. is more virulent than Aeromonas spp. in
cirrhotic patients.
Both pathogens are environmental pathogens in Taiwan,
related to exposure to wild water or marine creatures, and
often cause diseases among humans during warm seasons as
community-acquired infections. Vibrio infection was often
linked to warmer seasons in previous studies.4,5 However,
there were inconsistent opinions about the seasonal varia-
tion of Aeromonas bacteremia, because some studies re-
ported that it correlated with warmer seasons17 whereas
others did not.30 In this study, the seasonal variation was
relevant to warmer seasons, and is more evident in Vibrio
bacteremia (r2 Z 0.95, p < 0.0001) than in Aeromonas
bacteremia (r2 Z 0.74, p Z 0.006).
Furthermore, 23.4% (18 cases) of Aeromonas bacteremia
and 8.3% (4) of Vibrio bacteremia were nosocomial in-
fections, developing late during hospitalization, approxi-
mately 2 weeks after admission in Aeromonas bacteremia
but 1 week after admission in Vibrio bacteremia. Only one
patient with Vibrio bacteremia recalled recent seafood
ingestion. Because their portals of entry were not clear,
physicians should keep in mind the scenario thatAeromonas or Vibrio sepsis can develop even during hos-
pitalization and cause mortality. For cirrhotic patients,
food safety, including avoidance of raw or undercooked
food consumption, should be emphasized.
Most patients received appropriate empirical antibiotics,
but the mortality remained high in this study. Although no
prospective, controlled clinical trial can conclude optimal
therapeutic regimens for Vibrio infections, a combination
regimen with cefotaxime plus minocycline showed in vitro
synergistic antibacterial effects for Vibrio infections31,32
and was supported by a case series.33 However, Aeromonas
species possessed various b-lactamases, which can confer
resistance to a broad spectrum of antibiotics.10 For optimal
antibiotics against Aeromonas infections, species identifi-
cation and in vitro susceptibility are essential to guide
antimicrobial therapy.34
With the nature of a retrospective study, the exposure
history would not be retrieved with precision, which
underestimated the relevance of contact history in the
cases of Aeromonas bacteremia. In addition, polymicrobial
Aeromonas or Vibrio bacteremia was excluded, which may
influence the likelihood of environmental exposure.
Because other studies involving cases of polymicrobial
bacteremia reported the predominance of cancer pa-
tients,35,36 the study result of monomicrobial bacteremia in
cirrhotic individuals that the portals of entry in the cases of
Aeromonas infections are not always evident clinically,
remain valid.
In conclusion, in cirrhotic patients bacteremia caused by
Aeromonas and Vibrio species clustered during summer and
caused similar mortality, but Vibrio bacteremia led to a
more severe and fulminant sepsis.
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